相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study
Marya D. Zilberberg et al.
BMC INFECTIOUS DISEASES (2010)
A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients
Donald I. Hsu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp.
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Hospital Resource Utilization and Costs of Inappropriate Treatment of Candidemia
Heather M. Arnold et al.
PHARMACOTHERAPY (2010)
Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?
Michael A. Pfaller et al.
CURRENT FUNGAL INFECTION REPORTS (2010)
Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Comparison of 24-Hour and 48-Hour Voriconazole MICs as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) in Three Laboratories: Results Obtained with 2,162 Clinical Isolates of Candida spp. and Other Yeasts
Ana Espinel-Ingroff et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method
Luis Ostrosky-Zeichner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
EUCAST Technical Note on voriconazole - Subcommittee on antifungal susceptibility testing (AFST) of the ESCMID European committee for antimicrobial susceptibility testing (EUCAST)
J. L. Rodriguez-Tudela et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
EUCAST Definitive Document EDef 7.1:: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts
J. L. Rodriguez-Tudela et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
EUCAST Technical Note on fluconazole
J. -L. Rodriquez Tudela et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Timely selection of adequate antifungal therapy for candidemia in the critically ill: Don't let the yeast rise!
Alberto Corona et al.
CRITICAL CARE MEDICINE (2008)
Treatment-related risk factors for hospital mortality in Candida bloodstream infections
Andrew J. Labelle et al.
CRITICAL CARE MEDICINE (2008)
Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.:: Results from a global Antifungal Surveillance Program
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Potential confusion regarding the term 'resistance' in epidemiological surveys
S. Simjee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Posaconazole: A broad-spectrum triazole antifungal agent
Vijayalakshmi Nagappan et al.
CLINICAL INFECTIOUS DISEASES (2007)
Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections
Michael D. Parkins et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Posaconazole therapy for chronic refractory coccidioidomycosis
David A. Stevens et al.
CHEST (2007)
Invasive Candida species infection:: the importance of adequate empirical antifungal therapy
Darius Armstrong-James
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Setting and revising antibacterial susceptibility breakpoints
John Turnidge et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Does one voriconazole breakpoint suit all Candida species?
Maiken Cavling Arendrup et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Evaluation of etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole
Daniel J. Diekema et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study
Kevin W. Garey et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection
J. A. Vazquez et al.
HIV CLINICAL TRIALS (2007)
Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection
Daniel J. Skiest et al.
CLINICAL INFECTIOUS DISEASES (2007)
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
Oliver A. Cornely et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2007)
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study
Kevin W. Garey et al.
CLINICAL INFECTIOUS DISEASES (2006)
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions
II Raad et al.
CLINICAL INFECTIOUS DISEASES (2006)
Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values
J Turnidge et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Clinical significance of azole antifungal drug cross-resistance in Candida glabrata
Anil A. Panackal et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS
JA Vazquez et al.
CLINICAL INFECTIOUS DISEASES (2006)
Correlation of MIC with outcome for Candida species tested against voriconazole:: Analysis and proposal for interpretive breakpoints
MA Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection
AJ Ullmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Triazole cross-resistance among candida spp.: Case report, occurrence among bloodstream isolates, and implications for antifungal therapy
SS Magill et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
BJ Kullberg et al.
LANCET (2005)
Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazol
BD Alexander et al.
TRANSPLANTATION (2005)
Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality
M Morrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole itraconazole, posaconazole, and voriconazole for Candida spp.:: a collaborative study
A Espinel-Ingroff et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole
A Espinel-Ingroff et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
G Kahlmeter et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Voriconazole treatment for less-common, emerging, or refractory fungal infections
JR Perfect et al.
CLINICAL INFECTIOUS DISEASES (2003)
Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species
E Chryssanthou et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
R Herbrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
TJ Walsh et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2002)
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
R Ally et al.
CLINICAL INFECTIOUS DISEASES (2001)
Voriconazole: A second-generation triazole
PH Chandrasekar et al.
DRUGS OF TODAY (2001)
分享论文
